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appearance, he completely lost the power of locomotion, and
possessed no voluntary power but that of turning his head from side
to side, and of moving his toes. The skin remained quite sensible to
the touch, the functions of the primae viae and urinary organs
continued natural, and he had neither headache nor giddiness".
Nearly four months from the beginning of his illness his clinical
state was more or less unchanged. " ... he could not without a great
effort move even in a slight degree either the upper or the lower
extremities, but he could readily move his head and toes. The
functions of the organs of sense were entire. He had no difficulty in
voiding water: his appetite was good, and he had a daily alvine
discharge. His pulse was natural, he had no febrile symptoms, and
he was not much reduced in flesh. He stated, however, that for some
time previous to this illness, the abdomen had gradually become full
and tense, and several days previous to the attack he complained of
diarrhoea, at which period he had travelled on the outside of a coach
and caught cold".
Wardrop treated his patient by purging and in about three weeks
improvement began, with movement being restored to the fingers
and then the arm and legs. After four months he could walk without
assistance and he could write. "From this period he continued
perfectly well," Wardrop concluded, "and I saw him several years
afterwards in the enjoyment of good health, having never had any
return of the symptoms."
It is difficult to avoid the diagnosis of acute polyradiculoneuro-
pathy in this patient. He probably displayed at least seven of the
diagnostic criteria formulated by the National Institute of
Neurological and Communicative Disorders and Stroke,2 and there
was the history of gastrointestinal illness. Wardrop could not have
described loss of tendon jerks because their significance was not to
be realised until about 40 years later.3 Lumbar puncture for CSF
examination was not introduced for another 57 years.4 Landry’s
original description of "ascending paralysis" was in 1859. The first
report of the CSF findings by Guillain, Barre, and Strohl was
published in 1916, and this was amplified later.4
It would seem that Wardrop should have credit for the earliest
clinical description of this disease.
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TETRAHYDROAMINOACRIDINE AND THE
CENTRAL ANTICHOLINERGIC SYNDROME
SIR,-I was intrigued by your editorial (Jan 17, p 139) on the
cholinergic treatment of Alzheimer’s disease via oral tetrahydro-
aminoacridine (THA). Before the availability of short-duration,
non-depolarising muscle relaxants THA was often used during
general anaesthesia to prolong the very brief action of
suxamethonium to 15-20 min. Nowadays parenteral THA is only
available on a named patient basis, and oral THA has never been
available in the UK. When I regularly used THA to prolong the
action of suxamethonium I formed the clinical impression that
confused and elderly patients could sometimes be strikingly
brighter mentally in the postoperative period for a day or so. It is
interesting to speculate, in the light of your editorial, whether this
increased mental alertness might have been a consequence of
restored levels of cholinergic activity in the brain, though there are
other possible explanations.
The antimuscarinic properties of hyoscine and atropine make
these drugs valuable premedicants before the induction of general
anaesthesia. Hyoscine calms the central nervous system except in
elderly patients, in whom unacceptable agitation and confusion can
result. For this reason anaesthetists traditionally eschew the use of
hyoscine in patients over the age of 60 or 65. Older patients are
usually given atropine instead but perhaps a better choice is
glycopyrrolate, which has only peripheral anticholinergic effects in
premedication dosage. Apart from these considerations there is
generally little awareness amongst anaesthetists that they might be
harming patients by the unrestricted use of anticholinergic drugs.
The need to recognise that the central anticholinergic syndrome
(CAS)! can be precipitated by anaesthetists has been emphasised by
Rupreht and Dworacek.2 The mental impairment associated with
CAS ranges from simple memory disturbance to delirium and
coma. The prescribed treatment is the careful intravenous
administration of physotigmine salicylate. I have found this
treatment effective in patients with arteriopathy who have remained
agitated and confused 60-120 min postoperatively after apparently
adequate reversal of muscle relaxation and uneventful general
anaesthesia. The neostigmine used to reverse muscle relaxant drugs
does not cross the blood-brain barrier, unlike physostigmine, and
would not be expected to remedy the CAS. There is clearly an
important differential diagnosis to be made by the anaesthetist
between the confused agitation of incomplete reversal of the muscle
relaxant, the continued effects of other anaesthetic agents, and the
onset of CAS. Recognisable mental changes associated with CAS
can last a day or much longer in susceptible patients so that the
careful administration of physostigmine in these patients is justified.
It would be interesting to know whether THA, which can also cross
the blood-brain barrier, might be a suitable alternative parenteral
therapy. Peripheral muscarinic side-effects caused by both drugs
can be blocked with glycopyrrolate. The discomforts and possible
hazards of administering anticholinesterases parenterally make it
essential to consider very carefully whether a patient has CAS
before beginning treatment.
Further investigation of CAS is urgently required before it
becomes deeply engrained in the literature of anaesthesia. One
objection to the concept of CAS as a complication of anaesthesia is
that there is a multitude of neurotransmitters involved in the
ascending pathways that alert the cerebral cortex, all of which may
be altered by the complex effects of general anaesthesia.
Department of Anaesthesia,
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ALZHEIMER’S DISEASE AND
TETRAHYDROAMINOACRIDINE
SiR,&mdash;Your Jan 17 editorial, when referring to the trial of
Summers et al,l states that, apart from tetrahydroaminoacridine,
the patients took 1200 mg of lecithin daily. The paper states that all
patients were asked to take nine or more capsules of commercial
lecithin (1200 mg per capsule) or its equivalent per day-ie, a daily
intake of at least 10.80 g lecithin.
Medical Department,
E. Merck Ltd,
Alton, Hampshire GU34 5HG G. M. WHITFORD
1. Summers WK, Majovski LV, Marsh GM, et al. Oral tetrahydroaminoacridine m
long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315:
1241-45.
EICOSAPENTAENOIC ACID IN FAT
SiR,&mdash;The health effects of the m3-polyunsaturated fatty acid,
eicosapentaenoic acid (EPA; 20:5tn-3]), are of great interest.
Epidemiological investigations, however, are hampered by
problems in determining long-term dietary intake of EPA. Dietary
survey methods are imprecise and data on EPA in foods are scarce.
For the assessment of long-term individual intake of linoleic acid
(C18:2[n-6]), fat tissue microbiopsy has proved a reliable
alternative to survey methods, and a similar method for EPA would
be useful. Dr Wood and colleagues, in their paper on tissue fatty
acids and coronary heart disease (Jan 24, p 177), state that EPA is
not present in adipose tissue. We have now found that EPA can be
reliably detected in fat tissue microbiopsy specimens by capillary
gas/liquid chromatography (figure). In three healthy volunteers (a
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Detection of EPA in adipose tissue.
Peaks identified by comparison with pure standards. EPA (20:5[n-3])
content is 0.08% fatty acid methyl esters; detection limit about 0.01 %. Inset
compares putative EPA peak (lower) with peak when standard EPA (donated
by Dr G. Homstra) was added to the biopsy fatty acids.
Fatty acid methyl esters prepared from an 11 mg microbiopsy specimen2
were injected into a Packard gas chromatograph, split ratio 30:1, carrier gas
hydrogen 130 kPa, column WCOT fused silica 50m x 0-22 mm, coated with
0.2 pm ’CP-Sil 88’ (Chrompack, Middelburg, Netherlands), with oven
temperature 210&deg;C, FID detector, and injector 250&deg;C.
female student, a female technician, and a male staff member) we
found EPA levels of 0-07, 0 04, and 0 08 g per 100 g fatty acid
methyl esters, respectively. None of them ate a lot of fish.
Whetfier fat tissue EPA is a valid measure of EPA consumption
remains to be established.
Department of Human Nutrition,
Wageningen Agricultural University,
6703 BC Wageningen, Netherlands
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BODYBUILDER’S PSYCHOSIS
SIR,-Anabolic steroids are sometimes used by athletes seeking
gains in muscle size and strength.l,2 Although the medical effects
and risks of these drugs are well documented, their psychiatric
effects are largely unexplored.3-S
We have treated two men who required hospital admission for
psychotic episodes apparently associated with use of anabolic
steroids. A 40-year-old man had been prescribed methyl-
testosterone 10 ing twice daily for idiopathic impotence. Within 2
weeks he had symptoms meeting DSM-III criteria6 for major
depression, together with delusions of reference and visual and
auditory hallucinations. A 22-year-old construction worker and
bodybuilder took two 8-week courses ofmethandrostenolone 15 mg
daily. After the second course he had severe depressive symptoms.
Although the depression gradually lifted after several months
prominent paranoid and religious delusions ensued.
Extensive medical and neuroendocrine workup of both patients
was unremarkable. Both responded well to neuroleptics and were
able to discontinue these medications permanently after several
weeks. Neither patient reported any serious psychopathology
before the index episode. Both, with no further exposure to steroids,
have remained psychiatrically normal during more than two years’
follow-up. Thus, anabolic steroids emerge as a likely causative
factor in both cases.
Intrigued by these observations, we interviewed thirty-one
other anabolic steroid users (twenty-nine men), recruited by
advertisements at gymnasia in the Boston and Los Angeles areas.
Psychiatric diagnoses were made using a structured clinical
interview.’ Three men had had psychotic symptoms with steroids:
one reported auditory hallucinations of voices and noises lasting 5
weeks; another described delusions of reference and possible
thought broadcasting: a third reported paranoid delusions. At least
four others had "subthreshold" psychotic symptoms,’ including
referential thinking, paranoid jealousy, and grandiose beliefs. For
example, one man, while on steroids, believed that he could not be
injured if he fell from a third-floor window. All seven experienced
such symptoms only when taking orally active 17-alkylated steroids
(methandrostenolone, oxandrolone, and/or oxymetholone), alone
or in combination with parenteral preparations. None described any
psychotic symptoms, even at the subthreshold level, at any time
before steroid use.
Equally impressive was the observation that four interviewees
met criteria6 for manic episodes while taking anabolic steroids, and
five had major depression, either during or just after a course of the
drugs. Manic-like behaviours were prominent; one 23-year-old
twice bought expensive cars during courses of steroids and then was
forced to sell them afterwards. Another subject, taking
methandrostenolone, deliberately drove an old car into a tree at 60
km/h while a friend videotaped it. A third man, when "cut up" by
another driver in Boston, pursued and cornered the offender and
smashed his windshield with a crowbar. None of these subjects
described comparable behaviours when not using steroids.
McLean Hospital,
Belmont, Massachusetts 02178, USA;
and Harvard Medical School,
Boston
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BACK PAIN AND TESTICULAR GERM CELL
TUMOURS
SIR,-Dr Taylor (Feb 28, p 515) is correct in stating that germ
cell tumours with no evidence of a testicular primary are rare,
but patients are notoriously shy about reporting testicular
abnonnalities1 and even locally advanced tumours could escape
notice during a routine orthopaedic examination. Oncologists have
learned that back pain in cancer patients can indicate relapse in the
retroperitoneal lymph nodes.2 Relief of pain is then a useful clinical
marker of response to treatment.
We have found that severe, persistent back pain is the present-
ing feature of many malignancies in young people, including
lymphoma, testicular tumours, and carcinoma of the cervix (to be
published). Retroperitoneal lymphadenopathy can usually be
demonstrated in these patients by simple ultrasound examination.
It is important that the association between back pain and malignant
lymphadenopathy is more widely recognised so that these
potentially curable tumours are detected early.
Growth Regulation Laboratory,
Imperial Cancer Research Fund,
Lincoln’s Inn Fields,
London WC2A 3PX PENELLA J. WOLL
Department of Medical Oncology,
University of Glasgow ELAINE M. RANKIN
1. Jones WG, Appleyard I. Delay in diagnosing testicular tumours. Br Med J 1985; 290:
1550.
2. Smith D, Johnson R, James RD, Thatcher N. Upper abdominal lymphadenopathy as
first presentation of relapse, identified by ultrasonography, in patients treated for
small cell (oat cell) bronchogenic carcinoma. Br J Dis Chest 1985; 79: 141-46.
